Letters
Antipsychotics in dementia
Licensed indication for risperidone in dementia
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7337 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7337- David Phizackerley, deputy editor
- 1Drug and Therapeutics Bulletin, BMJ Evidence Centre, BMA House, London WC1H 9JR, UK
- dphizackerley{at}bmj.com
When referring to the licensed indication for risperidone, Corbett and colleagues state: “In Europe, only risperidone is currently licensed for use in dementia and only for up to six weeks in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.